Avian Aspergillosis in Birds: Aspergillus fumigatus Pathogenesis, Diagnosis, and Antifungal Treatment

Bottom line

Aspergillosis is the most common fungal disease of captive birds and a leading cause of respiratory and systemic morbidity and mortality, caused most often by Aspergillus fumigatus inhaled as ubiquitous environmental spores [1]. It is opportunistic: clinically important disease usually follows stress, immunosuppression, hypovitaminosis A, or heavy spore exposure from damp, poorly ventilated housing rather than simple contact [2]. Presentation is frequently insidious and late — nonspecific ill-thrift, dyspnea, tail-bob, and voice change — so diagnosis is multimodal, with endoscopic visualization of granulomas plus biopsy and culture the most definitive antemortem approach [1]. Treatment is prolonged systemic azole therapy (itraconazole or voriconazole), often with nebulization and endoscopic debulking, and the prognosis is guarded, especially in chronic disease [2].

Disease at a glance

Aspergillus species are saprophytic, ubiquitous environmental molds; A. fumigatus is by far the most common avian pathogen, with A. flavus and A. niger isolated less often [1]. Infection begins when inhaled conidia reach the respiratory tract. Birds are especially vulnerable because their unidirectional respiratory system carries spores deep into the air sacs, where low airflow and poor vascularization favor fungal establishment before spread to the lung and, in disseminated cases, to viscera [2].

Aspergillosis is opportunistic — the mold is a weak primary pathogen, and clinical disease usually requires a predisposing insult. Recognized risk factors include hypovitaminosis A and malnutrition, aspiration of food or medication, immunosuppression from concurrent disease, corticosteroid use, and heavy environmental spore loads from moldy feed or bedding, poor ventilation, and warm, humid housing [1].

Species predilection is well documented. Among companion psittacines, African grey parrots, Amazon parrots, cockatiels, and macaws are over-represented [1]. Beyond pet birds, raptors (including merlins and golden eagles), waterfowl, and captive penguins are classically high-risk groups [2].

Two clinical patterns are described. Acute aspergillosis follows overwhelming spore exposure — often in young, naïve, or heavily stressed birds — and produces rapid, diffuse airsacculitis and pneumonia [2]. Chronic (granulomatous) aspergillosis is the more common companion-bird form: focal or multifocal caseous granulomas, frequently at the syrinx or in the air sacs, build slowly in an immunocompromised host, and clinical signs surface only late [2].

Clinical signs are insidious and often late

Signs are nonspecific and typically emerge only after a substantial disease burden has accumulated, which is why aspergillosis is so often advanced at diagnosis [2]. Common findings include dyspnea, tail-bob, open-beak breathing, exercise intolerance, and increased respiratory effort, together with depression, anorexia, and progressive weight loss [1]. A change or loss of voice is a valuable clue: a syringeal or upper-respiratory granuloma classically produces "a sudden change in voice pitch during vocalization" in psittacines [2]. Chronic cases may add nonspecific ill-thrift, and hepatic involvement can produce biliverdinuria (green-tinged urates). Because none of these signs is specific, aspergillosis belongs on the differential for any bird with unexplained respiratory disease, wasting, or marked leukocytosis/monocytosis [1] — alongside bacterial disease and avian chlamydiosis (psittacosis).

Diagnosis is multimodal and antemortem confirmation is difficult

No single antemortem test reliably confirms avian aspergillosis, so diagnosis rests on integrating signalment, clinical signs, imaging, hematology, serology, and — when feasible — direct visualization [3].

Begin with a CBC and plasma protein electrophoresis. A leukocytosis with monocytosis is characteristic and, combined with compatible signs and radiographs, supports a strong presumptive diagnosis [1]; a "moderate to severe leukocytosis with heterophilia (25,000–100,000 cells/mcL)" and a decreased albumin:globulin ratio (<0.5) are reported to raise suspicion [2]. Plasma protein electrophoresis typically shows increased beta- (and often gamma-) globulins [1].

Imaging and serology add support but not certainty. Radiographs and CT can reveal airsacculitis, granulomas, and parenchymal disease, though early lesions are easily missed. Serodiagnosis is limited to antibody and antigen (galactomannan) detection, and these tests are imperfect: in one avian series, galactomannan at a 0.5 index cutoff had a sensitivity of 67% and specificity of 73%, protein electrophoresis reached 73% sensitivity and 70% specificity, and combining the two raised sensitivity to 89% but dropped specificity to 48% [4]. As of 2024, a systematic review concluded that none of the currently available antemortem tests provide sufficient accuracy to reliably detect Aspergillus infection in birds in clinical practice [5].

Definitive diagnosis therefore relies on endoscopy: direct visualization of the classic white-to-yellow fungal plaques or granulomas — often at the syrinx or air sacs — with biopsy for cytology, histopathology, and fungal culture is the most reliable antemortem confirmation [1]. Culture and PCR also allow species identification, which matters because susceptibility varies and resistance has been reported [3].

Treatment: prolonged systemic antifungals, nebulization, and debulking

Treatment is long (often months) and combines a systemic azole with adjunctive nebulization, endoscopic debulking of accessible granulomas, and correction of the underlying husbandry and nutritional deficits [1]. Critically, no antifungal is licensed for use in psittacine birds, so every regimen below is extra-label, and antifungal resistance has been reported in avian Aspergillus isolates [3].

Itraconazole (5–10 mg/kg PO q12–24h) is the most commonly used azole for systemic avian aspergillosis [1]; a typical protocol is 5–10 mg/kg PO q12h for 5 days, then q24h until resolution [2]. African grey parrots are more sensitive to the adverse effects of itraconazole — especially regurgitation and anorexia — and should be dosed at 5 mg/kg/day [1].

Voriconazole is preferred for resistant strains or itraconazole-intolerant birds; the Merck Veterinary Manual lists 12–18 mg/kg PO q12h [1]. A pharmacokinetic study in African grey parrots found that voriconazole has dose-dependent pharmacokinetics and may induce its own metabolism (lower troughs on repeated dosing), and recommended 12–18 mg/kg PO twice daily as a rational starting dose, noting higher doses may be needed over extended courses [6]. Voriconazole toxicity is real and species-specific: in a multi-institution penguin series, plasma concentrations above 30 µg/mL were associated with moderate-to-severe neurologic signs including ataxia, paresis, and seizures — well above human therapeutic levels of roughly 2–6 µg/mL — underscoring the value of therapeutic drug monitoring [7].

Terbinafine (10–15 mg/kg PO q12h) can be used with or in place of itraconazole [1]. Amphotericin B — the only fungicidal option — is given intratracheally (1 mg/kg through the glottis) and by nebulization (0.25–1 mg/mL in sterile water, never diluted in saline, which reduces its potency) [1]. Nebulized clotrimazole (10 mg/mL, 30 minutes twice daily) is a useful topical adjunct [1]. Continue systemic therapy for several weeks beyond clinical resolution, and monitor hepatic function during prolonged azole treatment [1].

Antifungal	Dose (extra-label)	Route / frequency
Itraconazole	5–10 mg/kg (African grey: 5 mg/kg/day)	PO q12–24h
Voriconazole	12–18 mg/kg	PO q12h
Terbinafine	10–15 mg/kg	PO q12h
Amphotericin B	1 mg/kg	Intratracheal
Clotrimazole	10 mg/mL	Nebulize 30 min, 2×/day

All doses per the Merck Veterinary Manual and are extra-label in birds; confirm against a current avian formulary before use [1].

Real-world outcomes are sobering. As of 2024, a retrospective of 14 psittacines treated with voriconazole (10–21 mg/kg, median 16 mg/kg, usually q12h; African greys were 8 of 14) reported that roughly 21% died or were euthanized within 24 days while about 29% survived beyond 12 months, with no adverse effects attributed to voriconazole in that series [8].

Prognosis and prevention

The prognosis for avian aspergillosis is guarded and depends on chronicity, the degree of immunosuppression, lesion burden, and species; acute fulminant disease and advanced chronic granulomas carry the worst outlook, and even successful cases often require months of therapy [2]. Because clinical disease is driven by host and environmental factors, prevention centers on lowering infection pressure and supporting the bird: maintain adequate ventilation with routine cleaning and disinfection, remove moldy feed and damp bedding, avoid unnecessary corticosteroids, minimize stress — recognizing that any acute stressor, from transport to reproductive emergencies such as egg binding and dystocia, can tip a subclinically colonized bird into clinical disease — and correct hypovitaminosis A and other nutritional deficits [3].

Frequently Asked Questions

What organism causes avian aspergillosis?

Aspergillus fumigatus is by far the most common cause, with A. flavus and A. niger isolated less often. It is an opportunistic environmental mold, so clinical disease usually follows a predisposing stressor, immunosuppression, hypovitaminosis A, or heavy spore exposure rather than simple contact [1].

Why is avian aspergillosis so difficult to diagnose antemortem?

Signs are nonspecific and appear late, and no serologic or antigen test is reliable on its own — as of 2024 a systematic review found none provide sufficient accuracy for clinical detection [5]. Galactomannan and protein electrophoresis have only moderate sensitivity and specificity [4], so endoscopic visualization of granulomas with biopsy and culture remains the most definitive antemortem approach [1].

Which birds are most at risk?

Companion psittacines such as African grey and Amazon parrots, cockatiels, and macaws are over-represented [1], as are raptors, waterfowl, and captive penguins [2]. Immunosuppression, hypovitaminosis A, chronic stress, corticosteroids, and moldy or poorly ventilated housing raise risk in any species [1].

What is the first-line antifungal, and how long is treatment?

Itraconazole (5–10 mg/kg PO q12–24h) is the most commonly used systemic azole, with voriconazole reserved for resistant strains or intolerant birds [1]. Treatment is prolonged — often months — and should continue for several weeks beyond clinical resolution, with hepatic monitoring during azole therapy [1]. All antifungal use in birds is extra-label.

Why must itraconazole be dosed lower in African grey parrots?

African greys are more sensitive to the adverse effects of itraconazole, especially regurgitation and anorexia, and should be dosed at 5 mg/kg/day rather than the standard 5–10 mg/kg q12–24h used in other species [1].

Is voriconazole safer than itraconazole?

Not universally. Voriconazole is valuable for resistant infections, but it has dose-dependent, self-inducing pharmacokinetics [6] and species-specific neurotoxicity — penguins with plasma levels above 30 µg/mL developed ataxia, paresis, and seizures — so therapeutic drug monitoring is advised where available [7].

What is the prognosis for a bird with aspergillosis?

Guarded. Outcome depends on chronicity, immune status, lesion burden, and species, and even treated birds often need months of therapy [2]. As of 2024, in a retrospective psittacine voriconazole series about 21% died or were euthanized within 24 days and about 29% survived beyond a year [8].

How is aspergillosis prevented in a collection?

Lower environmental infection pressure with adequate ventilation, routine cleaning and disinfection, and removal of moldy feed and damp bedding, and reduce host susceptibility by minimizing stress, avoiding unnecessary corticosteroids, and correcting vitamin A and other nutritional deficits [3].